Miscellaneous Disorders... with MCC DRG Reimbursement

Summary & Overview

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC: Inpatient Reimbursement Overview

DRG 640 encompasses miscellaneous disorders of nutrition, metabolism, fluids and electrolytes with a Major Complication or Comorbidity; it includes severe electrolyte disturbances and complex metabolic or nutrition-related conditions requiring inpatient care. This Diagnosis-Related Group matters for inpatient reimbursement because the Major Complication or Comorbidity designation increases case severity and typically results in higher Medicare payment compared with lower-severity groupings.

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCCDRG Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCCDRG 640Diagnosis-Related GroupInpatient ReimbursementMedicareInternal MedicineNephrologyEndocrinologyClinical Coding

DRG 640 Overview

DRG 640 covers inpatient cases grouped to miscellaneous disorders of nutrition, metabolism, fluids and electrolytes that include a Major Complication or Comorbidity. Typical clinical conditions include severe electrolyte disturbances, complex metabolic derangements, and significant nutrition-related complications that require hospital-level medical management and monitoring. This Diagnosis-Related Group is important for Medicare payment because presence of a Major Complication or Comorbidity generally increases resource use and results in higher reimbursement relative to non-major complication or comorbidity groupings. Accurate clinical documentation and coding determine whether a case is assigned to this Diagnosis-Related Group and thus affect payment.

National Payment Rates

Payor benchmarks for DRG 640 span from about $370 up to $44K across the national sample, with payer medians clustering between roughly $11K and $23K depending on carrier. The widest spread is observed between the lowest observed value ($370) and the highest ($44K). See the table and chart below for payer-specific distributions and percentile bands.

Mean Rates by Payer — National — DRG 640

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($12.1k), average submitted covered charges ($55.7k), average Medicare payment amount ($10.1k), and total discharges (73.7k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s reported DRG 640 means range from $21K (Anthem and Blue Cross Blue Shield) up to $32K (Cigna), reflecting a relatively narrow payer spread with one clear outlier on the high end. The presence of Cigna at $32K represents the most notable deviation from national averages, which are generally clustered lower for several large payers. See the table and chart below for payer-level detail.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of $32K, while Anthem and Blue Cross Blue Shield are tied at the lowest reported mean of $21K.
Alaska’s mean range ($21K–$32K) skews above some national payers but Cigna’s $32K mean notably exceeds national medians for several payers, indicating a meaningful upside vs. many national rates.

Clinical Trials

Acute inpatient management trials studying rapid correction strategies for severe electrolyte imbalances (such as profound hyponatremia, hyperkalemia, or severe acid–base disorders) in medically complex hospitalized adults. These studies enroll patients admitted with acute decompensations captured under DRG 640 to compare protocols for monitoring frequency, dosing algorithms for IV electrolyte replacement or removal, and safety endpoints like arrhythmia or osmotic demyelination. Results inform hospital protocols, length-of-stay, and resource use metrics that directly affect inpatient costs and reimbursement for cases with major complications.
Comparative effectiveness research evaluating nutrition support modalities and metabolic management in malnourished or catabolic inpatients with multisystem illness. Trials or observational cohorts compare approaches such as early enteral nutrition versus parenteral supplementation, protein-energy targets, or micronutrient repletion strategies in patients with comorbidities (e.g., renal dysfunction, liver disease, or sepsis) to assess impacts on infection rates, wound healing, metabolic derangements, and discharge disposition. Findings help clinicians tailor nutrition plans for high-risk patients and help payers understand downstream effects on readmissions, post-acute care needs, and overall episode costs.
Post-discharge outcomes and care-coordination studies targeting readmission prevention and long-term metabolic control after hospitalization for complex fluid, electrolyte, or nutritional disorders. These research projects follow patients discharged after an MCC-coded admission to evaluate transitional interventions such as structured follow-up, home-based monitoring of electrolytes and fluids, or patient education for medication and diet adherence, measuring 30- and 90-day readmission rates and functional outcomes. Evidence from these studies is relevant to hospitals and payers focused on reducing avoidable readmissions, optimizing post-acute resource allocation, and improving value-based payment performance.

Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Disorders without CC/MCC: Inpatient Reimbursement Overview

616-AMPUTATION-OF-LOWER-LIMB-FOR-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-DISORDERS-WITH-MCC

Amputation of Lower Limb for Endocrine, Nutritional and Metabolic Disorders with MCC: Inpatient Reimbursement Overview

623-SKIN-GRAFTS-AND-WOUND-DEBRIDEMENT-FOR-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-DISORDERS-WITH-CC

Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Disorders with CC: Inpatient Reimbursement Overview

619-O-R-PROCEDURES-FOR-OBESITY-WITH-MCC

O.R. Procedures for Obesity with MCC: Inpatient Reimbursement Overview

627-THYROID-PARATHYROID-AND-THYROGLOSSAL-PROCEDURES-WITHOUT-CC-MCC

Thyroid, Parathyroid and Thyroglossal Procedures without CC/MCC: Inpatient Reimbursement Overview

614-ADRENAL-AND-PITUITARY-PROCEDURES-WITH-CC-MCC

Adrenal and Pituitary Procedures with CC/MCC: Inpatient Reimbursement Overview

641-MISCELLANEOUS-DISORDERS-OF-NUTRITION-METABOLISM-FLUIDS-AND-ELECTROLYTES-WITHOUT-MCC

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes without MCC: Inpatient Reimbursement Overview

626-THYROID-PARATHYROID-AND-THYROGLOSSAL-PROCEDURES-WITH-CC

Thyroid, Parathyroid and Thyroglossal Procedures with CC: Inpatient Reimbursement Overview

639-DIABETES-WITHOUT-CC-MCC

Diabetes without CC/MCC: Inpatient Reimbursement Overview

630-OTHER-ENDOCRINE-NUTRITIONAL-AND-METABOLIC-O-R-PROCEDURES-WITHOUT-CC-MCC

Other Endocrine, Nutritional and Metabolic O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 25

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Miscellaneous Disorders of Nutrition, Metabolism, Fluids and Electrolytes with MCC: Inpatient Reimbursement Overview

DRG 640 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes